1,721,040 research outputs found
Ipertensione, diabete, fumo, dislipidemia e altri fattori di rischio cardiologici.
No full textCardioform. Corso di formazione e autovalutazione in Cardiologia. Fascicolo 8. Ipertensione, diabete, fumo, dislipidemia e altri fattori di rischio cardiologic
Effetti emodinamici ed umorali del Diltiazem nel trattamento dell'ipertensione arteriosa
No full textPsychiatric comorbidity and correlations among migraine, attachment, anxiety and depression: a controlled study
No full textThe association between migraine (M) and psychiatric comorbidity is well known even in children and adolescents. What is really difficult to understand is why this association is so common.
The aim of our study was to analyze the attachment style of children and adolescents with M and to try to understand how it could be correlated to anxiety (A) and or Depression (D) in migrain
Monitoraggio dei livelli ematici e degli effetti funzionali di due diverse formulazioni di teofillina slow-release.
No full textThe renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.
No full textAn association has been shown between plasma renin activity (PRA) and the risk of cardiovascular disease. There is also evidence that angiotensin II exerts detrimental effects on progression and instabilization of atherosclerotic plaque. The renin-angiotensin system (RAS) can be inhibited through inhibition of angiotensin I (Ang I) generation from angiotensinogen by direct renin inhibitors, inhibition of angiotensin II (Ang II) generation from angiotensin I by angiotensin-converting enzyme inhibitors and finally by direct inhibition of the action of Ang II receptor level. Aliskiren, the first direct renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic nonpeptide. Aliskiren blocks Ang I generation, while plasma renin concentration increases because the drugs blocks the negative feed-back exerted by Ang II on renin synthesis. Because of its long pharmacological half-life, aliskiren is suitable for once-daily administration. Its through-to-peak ratio approximates 98\% for the 300 mg/day dose. Because of its mechanism of action, aliskiren might offer the additional opportunity to inhibit progression of atherosclerosis at tissue level. Hypertension is an approved indication for this drug, which is also promising for the treatment of heart failure. The efficacy of this drug in reducing major clinical events is being tested in large ongoing clinical trials
Modificazioni anatomiche e funzionali del ventricolo sinistro in corso di trattamento antiipertensivo con Enalapril
No full textAlmitrine orale: effetti sugli scambi gassosi e sulla regolazione della ventilazione nelle pneumopatie croniche ostruttive. Studio controllato in doppio cieco.
No full textVentricular arrhythmias during long-term Chlorthalidone or Beta-blocker therapy in hypertensive patients
No full textPharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
No full textAzilsartan medoxomil is a newly approved angiotensin-receptor blocker for the management of hypertension. It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60\%. This new agent induces a potent and long-lasting antihypertensive effect. The effective therapeutic antihypertensive dosages of azilsartan medoxomil in humans vary from 40 to 80 mg/day.The authors review the results of clinical trials published in journals indexed in Medline, Scopus and Google Scholar. Primarily the authors discuss articles that analyze the safety and efficacy of azilsartan in lowering blood pressure.Clinical trials have demonstrated that azilsartan is superior to other angiotensin-receptor blockers in lowering blood pressure. However, the clinical blood pressure trials of azilsartan published to date have been mainly conducted in patients without serious comorbidities and it is not clear if azilsartan has advantages over other angiotensin-receptor blockers in the treatment of these types of hypertensive patients. In addition, it remains to be determined whether the specific pharmacologic and pharmacokinetic characteristics of azilsartan will have a clinically significant impact on long-term cardiovascular outcomes
- …
